Hercules Capital, Inc. (HCXY)
| Market Cap | 3.13B +1.7% |
| Revenue (ttm) | 566.17M +12.8% |
| Net Income | 380.33M +49.3% |
| EPS | 2.01 +33.8% |
| Shares Out | 184.59M |
| PE Ratio | 8.24 |
| Forward PE | 8.55 |
| Dividend | $1.56 (6.25%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | 100 |
| Open | 24.96 |
| Previous Close | 25.00 |
| Day's Range | 24.96 - 25.02 |
| 52-Week Range | 24.36 - 25.71 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 29, 2026 |
About HCXY
Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management ... [Read more]
News
Hercules Capital Announces the Appointment of Alfred B. Fichera to Its Board of Directors
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital's Investment Adviser Surpasses $2.3 Billion in Investable Capital
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty finance provider to innovative venture, gr...
Hercules Capital upgraded to Buy at UBS on better than average ROE
As previously reported, UBS upgraded Hercules Capital (HTGC) to Buy from Neutral with a price target of $18.50, up from $15.50, coming out of earnings for the business development company…
Hercules Capital upgraded to Buy from Neutral at UBS
UBS upgraded Hercules Capital (HTGC) to Buy from Neutral with an $18.50 price target
Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital price target lowered to $20 from $21 at Ladenburg
Ladenburg analyst Christopher Nolan lowered the firm’s price target on Hercules Capital (HTGC) to $20 from $21 and keeps a Buy rating on the shares.
Hercules Capital Earnings Call Transcript: Q2 2026
Record Q2 results included all-time highs in investment income and net investment income, with robust originations and strong portfolio credit quality. Liquidity and leverage improved, and the outlook remains positive with expectations for continued strong originations and normalized prepayments.
Hercules Capital Slides: Q2 2026
Hercules Capital has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Hercules Capital Earnings release: Q2 2026
Hercules Capital released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Hercules Capital Quarterly report: Q2 2026
Hercules Capital has published its Q2 2026 quarterly earnings report on July 30, 2026.
Hercules Capital reports Q2 NII 50c, consensus 48c
16:24 EDT Hercules Capital (HTGC) reports Q2 NII 50c, consensus 48c
Hercules Capital Reports Second Quarter 2026 Financial Results
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has closed an underwritten public offering of $325.0...
Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has priced an underwritten public offering of $325.0...
Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
Hercules Capital Transcript: AGM 2026
The meeting covered strong 2025 and Q1 2026 financial results, record new commitments, and a new supplemental dividend. All six shareholder proposals passed, including director election and plan amendments. The company highlighted its diversified portfolio and conservative balance sheet.
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE N...
Beren Therapeutics secures $300M financing
Beren Therapeutics has secured $300M in combined financing. The financing includes a $135M equity financing alongside up to $165M in a strategic financing facility with Hercules Capital (HTGC) across ...
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C., the parent company of Mandos LLC and a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, today announced...
Perk secures $300M credit facility
Perk announced the close of a $300M private credit facility led by Neuberger Speciality Finance, alongside Blue Owl Capital Inc. (OWL), Hercules Capital Inc. (HTGC) and Liquidity. The facility upsizes...
6 High-Yielding BDCs Safe Enough for Dividend Investors
It has been a scary few months for the sector, but the worst may be over. Here are sex BDC that offer exceptional dividend durability.
Hercules Capital price target raised to $15.50 from $15 at UBS
UBS raised the firm’s price target on Hercules Capital (HTGC) to $15.50 from $15 and keeps a Neutral rating on the shares.
HTGC Lawsuit Alleges CEO Allegedly Certified Misleading Statements - Hercules Capital Investors Face Losses Following CEO Allegedly Certified Misleading Statements: SueWallSt
Important Information Regarding Section 20(a) Individual Liability Claims Against Hercules Capital Officers NEW YORK, May 7, 2026 /PRNewswire/ -- SueWallSt alerts investors in Hercules Capital, Inc. (...